These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Brust P; van den Hoff J; Steinbach J Neurosci Bull; 2014 Oct; 30(5):777-811. PubMed ID: 25172118 [TBL] [Abstract][Full Text] [Related]
47. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions. Langer O J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172 [TBL] [Abstract][Full Text] [Related]
48. The role of imaging in proof of concept for CNS drug discovery and development. Wong DF; Tauscher J; Gründer G Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264 [TBL] [Abstract][Full Text] [Related]
49. Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging. Zheng MQ; Nabulsi N; Kim SJ; Tomasi G; Lin SF; Mitch C; Quimby S; Barth V; Rash K; Masters J; Navarro A; Seest E; Morris ED; Carson RE; Huang Y J Nucl Med; 2013 Mar; 54(3):455-63. PubMed ID: 23353688 [TBL] [Abstract][Full Text] [Related]
50. Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [ Nørgaard M; Ganz M; Svarer C; Frokjaer VG; Greve DN; Strother SC; Knudsen GM Neuroimage; 2019 Oct; 199():466-479. PubMed ID: 31158479 [TBL] [Abstract][Full Text] [Related]
51. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Bergström M; Grahnén A; Långström B Eur J Clin Pharmacol; 2003 Sep; 59(5-6):357-66. PubMed ID: 12937873 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([ Fu H; Tang W; Chen Z; Belov VV; Zhang G; Shao T; Zhang X; Yu Q; Rong J; Deng X; Han W; Myers SJ; Giffenig P; Wang L; Josephson L; Shao Y; Davenport AT; Daunais JB; Papisov M; Yuan H; Li Z; Traynelis SF; Liang SH ACS Chem Neurosci; 2019 May; 10(5):2263-2275. PubMed ID: 30698943 [TBL] [Abstract][Full Text] [Related]
53. Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Seneca N; Zoghbi SS; Skinbjerg M; Liow JS; Hong J; Sibley DR; Pike VW; Halldin C; Innis RB Synapse; 2008 Oct; 62(10):756-63. PubMed ID: 18651641 [TBL] [Abstract][Full Text] [Related]
54. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine. Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057 [TBL] [Abstract][Full Text] [Related]
55. Development of a Novel Carbon-11 Labeled PET Radioligand for Melanin- Concentrating Hormone Receptor 1. Igawa H; Stepanov V; Tari L; Okuda S; Yamamoto S; Kasai S; Nagisa Y; Haggkvist J; Svedberg M; Toth M; Takano A; Halldin C Curr Radiopharm; 2017; 10(1):35-40. PubMed ID: 28034352 [TBL] [Abstract][Full Text] [Related]
57. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Brooks DJ NeuroRx; 2005 Apr; 2(2):226-36. PubMed ID: 15897947 [TBL] [Abstract][Full Text] [Related]
59. Receptor Occupancy Imaging Studies in Oncology Drug Development. Burvenich IJG; Parakh S; Parslow AC; Lee ST; Gan HK; Scott AM AAPS J; 2018 Mar; 20(2):43. PubMed ID: 29520671 [TBL] [Abstract][Full Text] [Related]
60. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. Hostetler ED; Joshi AD; Sanabria-Bohórquez S; Fan H; Zeng Z; Purcell M; Gantert L; Riffel K; Williams M; O'Malley S; Miller P; Selnick HG; Gallicchio SN; Bell IM; Salvatore CA; Kane SA; Li CC; Hargreaves RJ; de Groot T; Bormans G; Van Hecken A; Derdelinckx I; de Hoon J; Reynders T; Declercq R; De Lepeleire I; Kennedy WP; Blanchard R; Marcantonio EE; Sur C; Cook JJ; Van Laere K; Evelhoch JL J Pharmacol Exp Ther; 2013 Nov; 347(2):478-86. PubMed ID: 23975906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]